The Experts below are selected from a list of 2610 Experts worldwide ranked by ideXlab platform
L Miele - One of the best experts on this subject based on the ideXlab platform.
-
notch signaling as a target in Multimodality Cancer Therapy
Current Opinion in Molecular Therapeutics, 2000Co-Authors: M S Jang, A Zlobin, W M Kast, L MieleAbstract:Notch signaling is an extremely conserved and widely used mechanism controlling cell fate determination. Recent evidence shows that Notch receptors regulate cell differentiation, proliferation and apoptosis in many cells, including neoplastic cells. In the context of Cancer experimental immunoTherapy and Multimodality Therapy, the Notch signaling network is acquiring increasing importance for its possible roles in both neoplastic cells and the immune system. In this review, we discuss: (i) the roles of Notch signaling in Cancer cells and the immune system; and (ii) strategies through which Notch-targeting biologicals may be used to increase the effectiveness of Multimodality Cancer treatment, including Cancer vaccines.
M S Jang - One of the best experts on this subject based on the ideXlab platform.
-
notch signaling as a target in Multimodality Cancer Therapy
Current Opinion in Molecular Therapeutics, 2000Co-Authors: M S Jang, A Zlobin, W M Kast, L MieleAbstract:Notch signaling is an extremely conserved and widely used mechanism controlling cell fate determination. Recent evidence shows that Notch receptors regulate cell differentiation, proliferation and apoptosis in many cells, including neoplastic cells. In the context of Cancer experimental immunoTherapy and Multimodality Therapy, the Notch signaling network is acquiring increasing importance for its possible roles in both neoplastic cells and the immune system. In this review, we discuss: (i) the roles of Notch signaling in Cancer cells and the immune system; and (ii) strategies through which Notch-targeting biologicals may be used to increase the effectiveness of Multimodality Cancer treatment, including Cancer vaccines.
Lawrence H Einhorn - One of the best experts on this subject based on the ideXlab platform.
-
survival after resection for metastatic testicular nonseminomatous germ cell Cancer to the lung or mediastinum
The Annals of Thoracic Surgery, 2011Co-Authors: Kenneth A Kesler, Laura E Kruter, Susan M Perkins, Karen M Rieger, Katherine J Sullivan, Matthew L Runyan, John W Brown, Lawrence H EinhornAbstract:Background Since the advent of cisplatin-based chemoTherapy, nonseminomatous germ cell tumors (NSGCT) have been considered one of the most curable solid neoplasms and a model for Multimodality Cancer Therapy. We undertook an institutional review of testicular NSGCT patients who underwent operations to remove lung or mediastinal metastases after chemoTherapy in the cisplatin era to determine outcomes. Methods From 1980 to 2006, 431 patients underwent 640 postchemoTherapy surgical procedures to remove lung (n = 159, 36.8%), mediastinal (n = 136, 31.6%), or both lung and mediastinal (n = 136, 31.6%) metastases within 2 years of chemoTherapy. Multiple variables potentially predictive of survival were analyzed. Results The overall median survival was 23.4 years, with 295 (68%) patients alive and well after an average follow-up of 5.6 years. There was no survival difference in patients who underwent removal of lung or mediastinal metastases. Pathologic categories of resected residual disease were necrosis (21.5%), teratoma (52.7%), persistent NSGCT (15.0%), and degenerative non-germ cell Cancer (10.1%). Multivariable analysis identified older age at time of diagnosis (p = 0.001), non-germ cell Cancer in testes specimen (p = 0.004), and pathology of residual disease (p Conclusions Patients who undergo resection of residual lung or mediastinal disease for metastatic testicular NSGCT as a planned approach after cisplatin-based chemoTherapy have overall excellent long-term survival. Survival is equivalent comparing hematogenous and lymphatic routes of metastases but depends on the pathology of the resected disease. These results justify an aggressive surgical approach, particularly to remove residual teratoma in the lung or mediastinum after chemoTherapy, including multiple surgical procedures if necessary.
A Zlobin - One of the best experts on this subject based on the ideXlab platform.
-
notch signaling as a target in Multimodality Cancer Therapy
Current Opinion in Molecular Therapeutics, 2000Co-Authors: M S Jang, A Zlobin, W M Kast, L MieleAbstract:Notch signaling is an extremely conserved and widely used mechanism controlling cell fate determination. Recent evidence shows that Notch receptors regulate cell differentiation, proliferation and apoptosis in many cells, including neoplastic cells. In the context of Cancer experimental immunoTherapy and Multimodality Therapy, the Notch signaling network is acquiring increasing importance for its possible roles in both neoplastic cells and the immune system. In this review, we discuss: (i) the roles of Notch signaling in Cancer cells and the immune system; and (ii) strategies through which Notch-targeting biologicals may be used to increase the effectiveness of Multimodality Cancer treatment, including Cancer vaccines.
W M Kast - One of the best experts on this subject based on the ideXlab platform.
-
notch signaling as a target in Multimodality Cancer Therapy
Current Opinion in Molecular Therapeutics, 2000Co-Authors: M S Jang, A Zlobin, W M Kast, L MieleAbstract:Notch signaling is an extremely conserved and widely used mechanism controlling cell fate determination. Recent evidence shows that Notch receptors regulate cell differentiation, proliferation and apoptosis in many cells, including neoplastic cells. In the context of Cancer experimental immunoTherapy and Multimodality Therapy, the Notch signaling network is acquiring increasing importance for its possible roles in both neoplastic cells and the immune system. In this review, we discuss: (i) the roles of Notch signaling in Cancer cells and the immune system; and (ii) strategies through which Notch-targeting biologicals may be used to increase the effectiveness of Multimodality Cancer treatment, including Cancer vaccines.